# Sinovent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sinovent

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.sinovent.com.cn/
- Total disclosed funding: $243M
- Latest round: Series E (Feb 20, 2024)
- Investors on record: 18

## About

Founded in 2017 and based in Suzhou, China, Sinovent operates as a biopharmaceuticals firm that offers small molecule drug research and development services. The company has set up branch offices in Boston, Beijing, Shanghai, and Sydney. There are 252 employees in the company. In August 2020, it raised CNY 1 billion in series C funding. In February 2024, Sinovent raised CNY 700 million in series E funding. 

Sinovent has developed a pipeline of innovative drugs such as BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and new-generation ADCs, utilizing its own technology platforms of targeted therapies, anti-infectives, and PROTACs. XNW4107 is a ß-lactamase broad-spectrum anti-drug-resistant bacterial drug with antimicrobial efficacy against Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and carbapenem antibiotic-resistant Enterobacteriaceae (CRE). EZH2 inhibitor XNW5004 can be used to treat blood cancer and prostate cancer. And XNW3009 is a uric acid-lowering drug.

The company’s revenue is generated by providing drugs for treating diseases such as tumors, anti-infections and metabolism.

The company will continue to improve the technology platforms of targeted therapy, anti-infection and PROTAC, and accelerate the operation of production bases as well as the construction of commercialization teams.

## Funding rounds

- Series E, Feb 20, 2024, $97M — T-Capital, Loyal Valley Capital, Chen Hai Capital, Shanghai Guoxin Venture Capital Investment, Pudong Venture Capital, Suzhou Zhuopu Fund Management, Jinan Jingfa Capital, Yuekai Capital, Tencent Investment
- Series C, Aug 25, 2020, $146M — China International Capital Corporation, Loyal Valley Capital, Jiuyo Capital, Oceanpine Capital, Rotex Inc., Shanghai Deguan Asset Management
- Series B, Jun 26, 2019 — Suzhou International Development Venture Capital Holding, Apricot Capital, Ming Bioventures
- Series A, May 24, 2018 — Loyal Valley Capital, Apricot Capital, Lepu Medical Technology Beijing

## Investors

- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A, Series C, Series E
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A, Series B
- Lepu Medical Technology Beijing — Series A
- Suzhou International Development Venture Capital Holding (https://capitalatlas.ai/funds/suzhou-international-development-venture-capital-holding) — Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C
- Rotex Inc. — Series C
- Shanghai Deguan Asset Management (https://capitalatlas.ai/funds/shanghai-deguan-asset-management) — Series C
- T-Capital — Series E
- Chen Hai Capital (https://capitalatlas.ai/funds/chen-hai-capital) — Series E
- Shanghai Guoxin Venture Capital Investment — Series E
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series E
- Suzhou Zhuopu Fund Management — Series E
- Jinan Jingfa Capital (https://capitalatlas.ai/funds/jinan-jingfa-capital) — Series E
- Yuekai Capital (https://capitalatlas.ai/funds/yuekai-capital) — Series E
- Tencent Investment — Series E